ZW 25

Next Previous
Drug Profile

ZW 25

Alternative Names: ZW25

Latest Information Update: 05 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Zymeworks
  • Class Antineoplastics; Bispecific antibodies
  • Mechanism of Action ERBB 2 receptor antagonists; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer; Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Breast cancer; Gastric cancer; Ovarian cancer

Most Recent Events

  • 28 Feb 2018 Zymeworks submitted Clinical Trial Application to Health Canada for phase I trial in Breast cancer and Gastric cancer before February 2018
  • 05 Dec 2017 Zymeworks intends to submit an initial Biologics License Application for ZW 25 in 2021
  • 05 Dec 2017 Updated efficacy data from a phase I trial in Breast cancer and Gastric cancer released by Zymeworks
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top